Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Donna Smolenski

Nurse Practitioner, Psychiatric/Mental Health Myrtle Beach, SC Nurse Practitioner

NPI 1457997462 CMS profile 10970350

3025 Newcastle Loop, Myrtle Beach, SC 29588

Open in the dashboard

General payments

$7,508

360 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Donna Smolenski of Myrtle Beach, SC is reported in the CMS Open Payments database as having received $7,508 across 360 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,232 111
2024 General $2,142 93
2023 General $2,141 106
2022 General $435 24
2021 General $558 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Donna Smolenski
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Donna Smolenski were reported at $2,232. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Donna Smolenski Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $558 $166 $54–$482 $132
2022 $435 $195 $66–$559 $149
2023 $2,141 $233 $82–$673 $160
2024 $2,142 $236 $84–$688 $164
2025 $2,232 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,859 156 payments
  2. Otsuka America Pharmaceutical, Inc. $736 26 payments
  3. Axsome Therapeutics, Inc. $707 18 payments
  4. Janssen Pharmaceuticals, Inc $488 19 payments
  5. Neurocrine Biosciences, Inc. $480 12 payments
  6. ITI, Inc. $427 17 payments
  7. Alkermes, Inc. $375 14 payments
  8. Teva Pharmaceuticals USA, Inc. $347 20 payments
  9. Lundbeck LLC $255 11 payments
  10. Vanda Pharmaceuticals Inc. $234 11 payments
  11. Other $1,600 56 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,444 358 payments
  2. Education $64 2 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR Neuroscience $1,319 112 payments
  2. REXULTI $699 24 payments
  3. VRAYLAR Neuroscience $540 44 payments
  4. INGREZZA $480 12 payments
  5. Auvelity $417 6 payments
  6. CAPLYTA $354 13 payments
  7. SPRAVATO $299 8 payments
  8. Sunosi $290 12 payments
  9. LYBALVI $274 9 payments
  10. ABILIFY MAINTENA $242 12 payments
  11. Other $4,363 176 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

517

Median for Nurse Practitioner: 389

Drug cost

$230,364

Median for Nurse Practitioner: $21,885

Branded share of claims

16.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Austedo Xr Deutetrabenazine Brand 30 $218,712
Duloxetine Hcl Generic 28 $2,989
Sertraline Hcl Generic 41 $1,513
Olanzapine Odt Olanzapine Brand 15 $1,200
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 13 $809
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 27 $736
Mirtazapine Generic 27 $613
Divalproex Sodium Generic 31 $571
Quetiapine Fumarate Generic 41 $535
Aripiprazole Generic 19 $452

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$23,543

Medicare's payments for the services billed

Medicare patients

57

Average age 67

Services billed

426

38 women, 19 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Depression 63%
Arthritis 46%
Diabetes 30%
Ischemic heart disease 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $380
$380 — —
CAPLYTA
  • ITI, Inc. $255
$255 — —
REXULTI
  • Lundbeck LLC $116
  • Otsuka America Pharmaceutical, Inc. $83
$199 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $169
$169 — —
QUVIVIQ
  • IDORSIA PHARMACEUTICALS US INC $114
$114 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

360 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record